Skip Navigation



JAC Advance Access published online on June 6, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl237
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/2/458    most recent
dkl237v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Posteraro, B.
Right arrow Articles by Fadda, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Posteraro, B.
Right arrow Articles by Fadda, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received March 16, 2006
Revised May 10, 2006
Accepted May 12, 2006

Brief report

Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes

Brunella Posteraro 1, Maurizio Sanguinetti 1 *, Barbara Fiori 1, Marilena La Sorda 1, Teresa Spanu 1, Dominique Sanglard 2, and Giovanni Fadda 1

1 Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy
2 Institut de Microbiologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

* To whom correspondence should be addressed.
Maurizio Sanguinetti, E-mail: msanguinetti{at}rm.unicatt.it


  Abstract

Objectives: Several studies have documented the potent in vitro activity of caspofungin against Candida spp. This is of special concern for Candida glabrata infections that are often resistant to many azole antifungal agents and, consequently, difficult to treat. The aim of the present study was to expand the data on the in vitro activity of caspofungin against azole-resistant isolates of C. glabrata.

Methods: A total of 50 clinical isolates of C. glabrata were tested for susceptibility to caspofungin. The isolates were cross-resistant to multiple azoles, including fluconazole, itraconazole, ketoconazole and voriconazole. Expression of the resistance-related CgCDR1 and CgCDR2 genes was evaluated by quantitative RT-PCR analysis. The MICs of caspofungin were determined by using the National Committee for Clinical Laboratory Standards M27-A2 reference method.

Results: C. glabrata isolates exhibited increased expression of the CDR efflux pump(s), and this was in accordance with their high-level azole resistance. In contrast, all the isolates were highly susceptible to caspofungin (100% of isolates were inhibited at ≤1 mg/L).

Conclusions: Our results represent further evidence for the excellent antifungal potency of caspofungin, particularly against C. glabrata isolates expressing cross-resistance to azoles.

Keywords: antifungals; susceptibility testing; CgCDR genes.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
M. Tumbarello, M. Sanguinetti, E. M. Trecarichi, M. La Sorda, M. Rossi, E. de Carolis, K. de Gaetano Donati, G. Fadda, R. Cauda, and B. Posteraro
Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome
J. Antimicrob. Chemother., December 1, 2008; 62(6): 1379 - 1385.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.